聚(N(5)-(3-羟基丙基)-1-谷氨酰胺) | 25569-41-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 聚(N(5)-(3-羟基丙基)-1-谷氨酰胺)
• 英文名称: Hydroxypropylglutamine
• 英文别名: (2S)-5-amino-2-(3-hydroxypropylamino)-5-oxopentanoic acid
• CAS: 25569-41-9
• 化学式: C₈H₁₆N₂O₄
• 分子量: 204.22
• InChiKey: MEALETCBCJNEFX-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  、 、 Sodium Hydrosulfite, 85per cent 、 L-谷氨酸 、 聚(N(5)-(3-羟基丙基)-1-谷氨酰胺) 以 碳酸氢钠 为溶剂， 反应 1.0h， 生成 4-氨基-L-苯丙氨酸
  参考文献：
  名称：

  Water-soluble, physiologically active, synthetic copolypeptides

  摘要：

  具有高生理活性和长效作用的水溶性共聚肽包括水溶性线性共聚肽，其在其聚合骨架上至少连接有一个具有以下结构的取代基：##STR1## 其中Z是源自生理活性化合物的芳香基团，x是一个整数，等于0或1。

  公开号：

  US04116949A1

文献信息

• Drug-carrier conjugates
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：EP0094844A2

  公开（公告）日：1983-11-23

  Biologically active drugs, e.g. catecholamine hormones, are coupled to carrier molecules, e.g. monodisperse peptides to produce conjugate molecules. The conjugate molecules retain biological activity, but the pharmacokinetic, pharmacodynamic and/or potency properties of the drug is modified. The drug is coupled to the carrier via a spacer moiety which not only serves to covalently link the drug to the carrier, but also insulates the biologically active portion of the drug, i.e., the pharmacophore, from degradation during the coupling process. The carrier preferably consists of a monodisperse peptide in which the sequence of amino acid residues is carefully preselected and controlled.

  生物活性药物（如儿茶酚胺激素）与载体分子（如单分散肽）偶联生成共轭分子。共轭分子保留了生物活性，但药物的药代动力学、药效学和/或效力特性有所改变。药物通过间隔分子与载体偶联，间隔分子不仅能使药物与载体共价连接，还能使药物的生物活性部分（即药效基团）在偶联过程中不被降解。载体最好由单分散肽组成，其中的氨基酸残基序列经过精心预选和控制。
• Advanced anticancer therapy and cytotoxic medicaments for its implementation
  申请人：IntraCel Corporation

  公开号：EP0259904A1

  公开（公告）日：1988-03-16

  A therapeutic composition comprising a chemical conjugate including a first moiety, other than an immunoglobulin or fragment thereof, such as epidermal growth factor, which preferentially binds to a tumor cell, and is internalized by the cell, and a second moiety linked to the first moiety, and comprising a biodegradable polymeric carrier, such as polyglutamic acid, to which one or more cytotoxic molecules, for instance, daunomycin, are attached. The degradation of the carrier by intracellular enzymes releases a cytotoxic agent, resulting in selective destruction of the tumor cells.

  一种治疗组合物，包括一种化学共轭物，其中第一分子（免疫球蛋白或其片段除外），如表皮生长因子，优先与肿瘤细胞结合，并被细胞内化；第二分子与第一分子相连；还包括一种可生物降解的聚合载体，如聚谷氨酸，其上附有一种或多种细胞毒性分子，如daunomycin。 载体被细胞内酶降解后释放出细胞毒剂，从而选择性地破坏肿瘤细胞。
• Nanoparticles with protected interiors, and methods of use thereof
  申请人：Universidade de Santiago de Compostela

  公开号：US10471020B2

  公开（公告）日：2019-11-12

  The present invention generally relates to particles, including nanoparticles, for example, for drug delivery or other applications. Certain aspects of the present invention are generally directed to particles, such as nanoparticles, comprising an inner portion and a coating. The inner portion may contain insulin or other therapeutic molecules for delivery to a living organism. In some cases, the molecules may be electrostatically complexed with an oppositely-charged peptide, such as an oligoarginine, or other species. The therapeutic molecules may also be water soluble. In some cases, the peptide may be conjugated to a hydrophobic portion, such as cholesterol, lauric acid, or a fatty acid chain. This hydrophobic modification may facilitate complex formation with the therapeutic molecule and the stability of the resulting complex. The complex typically is surrounded by a coating, which may protect the complex. For example, the coating may include polymers such as poly(glutamic acid) and poly(ethylene glycol). In some cases, the coated complex may also facilitate transport across cells, e.g., within the gastrointestinal tract. Other aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

  本发明一般涉及颗粒，包括纳米颗粒，例如，用于药物输送或其他应用。本发明的某些方面通常针对颗粒，如纳米颗粒，包括内部部分和涂层。内部部分可包含胰岛素或其他治疗分子，用于向活生物体递送。在某些情况下，这些分子可与带相反电荷的肽，如低聚精氨酸，或其他物质进行静电络合。治疗分子也可以是水溶性的。在某些情况下，肽可与疏水部分（如胆固醇、月桂酸或脂肪酸链）共轭。这种疏水修饰可促进与治疗分子形成复合物，并提高复合物的稳定性。复合物周围通常有一层可保护复合物的涂层。例如，涂层可包括聚（谷氨酸）和聚（乙二醇）等聚合物。在某些情况下，涂层复合物还可促进细胞间的转运，例如在胃肠道内的转运。本发明的其它方面一般涉及制造或使用此类组合物的方法、包括此类组合物的试剂盒或类似物。
• Protection of progenitor cells and regulation of their differentiation
  申请人：Proteobioactives Pty Ltd

  公开号：US10609922B2

  公开（公告）日：2020-04-07

  The present invention relates to the use of polysulfated polysaccharides in combination with progenitor cells to improve the viability of the progenitor cells including improving the cryopreservation of the progenitor cells and provides novel compositions, methods and uses. The present invention also relates to the use of polysulfated polysaccharides to regulate the proliferation and differentiation of progenitor cells.

  本发明涉及将多硫酸化多糖与祖细胞结合使用，以提高祖细胞的活力，包括改善祖细胞的冷冻保存，并提供了新颖的组合物、方法和用途。本发明还涉及使用多硫酸化多糖来调节祖细胞的增殖和分化。
• Processes for making polyisobutylene compositions
  申请人：NTP Tec, LLC

  公开号：US10640590B2

  公开（公告）日：2020-05-05

  Methods of making polyisobutylene and catalyst systems are described. Polyisobutylene compositions and catalyst system compositions are also described. In some embodiments, a method of making a catalyst system includes: providing a support material; calcining the support material; and forming a catalyst system by adding to the support material (a) a mixture comprising BF3, (b) a mixture comprising BF3 and a complexing agent, or (c) both. In some embodiments, a method of making a polymer composition includes providing a catalyst system comprising: (a) a support material selected from the group consisting of Al2O3, ZrO2, TiO2, SnO2, CeO2, SiO2, SiO2/Al2O3, and combinations thereof; and (b) BF3; providing a feedstock comprising isobutylene; forming a reaction mixture comprising the feedstock and the catalyst system; contacting the isobutylene with the catalyst system; and obtaining a polymer composition.

  描述了制造聚异丁烯和催化剂体系的方法。还描述了聚异丁烯组合物和催化剂体系组合物。在一些实施例中，制造催化剂体系的方法包括：提供一种支撑材料；煅烧支撑材料；以及通过向支撑材料中加入（a）包含 BF3 的混合物、（b）包含 和络合剂的混合物或（c）两者形成催化剂体系。在一些实施例中，制造聚合物组合物的方法包括提供催化剂体系，该催化剂体系包括：(a) 选自 Al2O3、ZrO2、TiO2、SnO2、CeO2、SiO2、SiO2/Al2O3 及其组合的组的支撑材料；和(b) ；提供包含异丁烯的原料；形成包含原料和催化剂体系的反应混合物；使异丁烯与催化剂体系接触；和获得聚合物组合物。